Display options
Cite
Leyden JJ, Preston N, Osborn C, et al. In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes. J Clin Aesthet Dermatol. 2011;4(5):22-6
Leyden, J. J., Preston, N., Osborn, C., & Gottschalk, R. W. (2011). In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes. The Journal of clinical and aesthetic dermatology, 4(5), 22-6.
Leyden, James J, et al. "In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes." The Journal of clinical and aesthetic dermatology vol. 4,5 (2011): 22-6.
Leyden JJ, Preston N, Osborn C, Gottschalk RW. In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes. J Clin Aesthet Dermatol. 2011 May;4(5):22-6. PMID: 21607190; PMCID: PMC3100113.
Copy Download .nbib Format: NLM
Share it on

J Clin Aesthet Dermatol. 2011 May;4(5):22-6.

In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes.

The Journal of clinical and aesthetic dermatology

James J Leyden, Norman Preston, Cris Osborn, Ronald W Gottschalk

PMID: 21607190 PMCID: PMC3100113

Abstract

BACKGROUND: A gel combination treatment containing a retinoid (adapalene 0.1%) and an antimicrobial (benzoyl peroxide 2.5%) has been shown to be an effective treatment for acne vulgaris, addressing three of the four pathogenic factors (hyperkeratinization, Propionibacterium acnes proliferation, inflammation) without contributing to the incidence of Propionibacterium acnes antibiotic resistance as neither the retinoid nor benzoyl peroxide creates selective pressure for resistance.

OBJECTIVE: To evaluate the effectiveness of an adapalene-benzoyl peroxide gel combination in reducing antibiotic-sensitive and resistant strains of Propionibacterium acnes on the facial skin of volunteers.

METHODS: This four-week, open-label, single-center study included 30 healthy adults with high facial Propionibacterium acnes populations [>10(4) colony-forming units per square centimeter of skin (CFU/cm(2))] and presence of subpopulations resistant to erythromycin, tetracycline, and clindamycin. The gel was applied once daily to the forehead. Cultures for total and antibiotic-resistant Propionibacterium acnes were obtained from the forehead area at screening, Baseline, Week 2, and Week 4.

RESULTS: Total Propionibacterium acnes counts decreased by 1.1 log(10) CFU/cm(2) after two weeks of treatment, and by 1.6 log10 CFU/cm(2) after four weeks. All subjects had strains resistant to each of the five antibiotics at baseline. Mean counts of erythromycin and clindamycin resistant Propionibacterium acnes were high at baseline (5.37 and 5.28 log(10) CFU/cm(2), respectively) and decreased by ≥2.1 log(10) by Week 4 (P<0.001). Mean counts of strains resistant to tetracyclines were lower at baseline (3.8 to 4.2 CFU/cm(2)) and decreased by 1.9 (tetracycline), 2.4 (minocycline), and 1.3 (doxycycline) log(10) CFU/cm(2) by Week 4 (P<0.001).

LIMITATIONS: Although limited in scope, the results of the present study demonstrate that the fixed-dose combination gel containing adapalene 0.1% and benzoyl peroxide 2.5% effectively inhibited both antibiotic-susceptible and antibiotic-resistant Propionibacterium acnes. In addition to reducing population densities, therapy with adapalene-benzoyl peroxide eradicated some resistant strains entirely in some individual subjects.

CONCLUSION: Topical adapalene-benzoyl peroxide gel effectively reduced skin colonization by antibiotic-sensitive and antibiotic-resistant Propionibacterium acnes after four weeks. This trial was registered with ClinicalTrials.gov (http://clinicaltrials.gov/), registry number NCT00907101.

References

  1. Eur J Dermatol. 2004 Jan-Feb;14(1):4-12 - PubMed
  2. Skin Pharmacol Physiol. 2006;19(5):283-9 - PubMed
  3. J Invest Dermatol. 1965 Dec;45(6):498-503 - PubMed
  4. Med J Aust. 1998 Sep 7;169(5):259-61 - PubMed
  5. Br J Dermatol. 1995 Feb;132(2):204-8 - PubMed
  6. Drugs. 1997 Mar;53(3):511-9 - PubMed
  7. BMJ. 2002 Aug 31;325(7362):475-9 - PubMed
  8. Infect Disord Drug Targets. 2008 Sep;8(3):156-9 - PubMed
  9. Dermatology. 1998;196(1):119-25 - PubMed
  10. Cutis. 2008 Nov;82(5):336-42 - PubMed
  11. Br J Dermatol. 2009 Nov;161(5):1180-9 - PubMed
  12. J Am Acad Dermatol. 2009 May;60(5 Suppl):S1-50 - PubMed
  13. Br J Dermatol. 2002 May;146(5):840-8 - PubMed
  14. Cutis. 2007 Jul;80(1 Suppl):5-9 - PubMed
  15. Arch Dermatol Res. 1979 May 4;264(3):369-71 - PubMed
  16. Clin Ther. 2002 Jul;24(7):1117-33 - PubMed
  17. Ann Acad Med Singap. 2001 Jan;30(1):22-5 - PubMed
  18. J Cutan Pathol. 1974;1(5):191-200 - PubMed
  19. Arch Dermatol. 1983 Jul;119(7):577-9 - PubMed
  20. Br J Dermatol. 2003 Mar;148(3):467-78 - PubMed
  21. J Am Acad Dermatol. 1983 Jan;8(1):41-5 - PubMed
  22. Br J Dermatol. 1989 Jul;121(1):51-7 - PubMed
  23. J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37 - PubMed
  24. Br J Dermatol. 2001 Feb;144(2):339-46 - PubMed
  25. Adv Ther. 2002 May-Jun;19(3):109-18 - PubMed
  26. Dermatol Clin. 2009 Jan;27(1):1-15 - PubMed
  27. Br J Dermatol. 1998 Oct;139 Suppl 52:3-7 - PubMed
  28. Am J Clin Dermatol. 2001;2(4):263-6 - PubMed
  29. Dermatol Clin. 2009 Jan;27(1):17-24 - PubMed
  30. J Dermatolog Treat. 2002 Sep;13(3):107-10 - PubMed
  31. Eur J Dermatol. 2001 Nov-Dec;11(6):549-53 - PubMed
  32. Lancet. 2004 Dec 18-31;364(9452):2188-95 - PubMed
  33. Cutis. 2008 Dec;82(6):417-21 - PubMed
  34. J Clin Microbiol. 1990 May;28(5):941-3 - PubMed
  35. J Am Acad Dermatol. 1997 Jun;36(6 Pt 2):S96-103 - PubMed
  36. Cutis. 2009 Aug;84(2):110-6 - PubMed
  37. Int J Dermatol. 2003 Dec;42(12):925-7 - PubMed
  38. J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):710-6 - PubMed
  39. J Drugs Dermatol. 2009 Jul;8(7):657-61 - PubMed
  40. J Am Acad Dermatol. 2007 Nov;57(5):791-9 - PubMed

Publication Types